Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Germline Mutations in CIDEB and Protection against Liver Disease
Niek Verweij, Mary E. Haas, Jonas B. Nielsen, et al.
New England Journal of Medicine (2022) Vol. 387, Iss. 4, pp. 332-344
Open Access | Times Cited: 78

Showing 1-25 of 78 citing articles:

AASLD Practice Guidance on the clinical assessment and management of nonalcoholic fatty liver disease
Mary E. Rinella, Brent A. Neuschwander‐Tetri, Mohammad Shadab Siddiqui, et al.
Hepatology (2023) Vol. 77, Iss. 5, pp. 1797-1835
Open Access | Times Cited: 1150
EASL–EASD–EASO Clinical Practice Guidelines on the management of metabolic dysfunction-associated steatotic liver disease (MASLD)
Frank Tacke, Paul Horn, Vincent Wai‐Sun Wong, et al.
Journal of Hepatology (2024) Vol. 81, Iss. 3, pp. 492-542
Closed Access | Times Cited: 314
Lipid droplet biogenesis and functions in health and disease
Armella Zadoorian, Ximing Du, Hongyuan Yang
Nature Reviews Endocrinology (2023) Vol. 19, Iss. 8, pp. 443-459
Open Access | Times Cited: 249
Using genetic association data to guide drug discovery and development: Review of methods and applications
Stephen Burgess, Amy M. Mason, Andrew J. Grant, et al.
The American Journal of Human Genetics (2023) Vol. 110, Iss. 2, pp. 195-214
Open Access | Times Cited: 101
EASL-EASD-EASO Clinical Practice Guidelines on the Management of Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD)
Frank Tacke, Paul Horn, Vincent Wai‐Sun Wong, et al.
Obesity Facts (2024) Vol. 17, Iss. 4, pp. 374-444
Open Access | Times Cited: 59
Found in translation—Fibrosis in metabolic dysfunction–associated steatohepatitis (MASH)
Shuang Wang, Scott L. Friedman
Science Translational Medicine (2023) Vol. 15, Iss. 716
Open Access | Times Cited: 55
Therapeutic opportunities for the treatment of NASH with genetically validated targets
Daniel Lindén, Stefano Romeo
Journal of Hepatology (2023) Vol. 79, Iss. 4, pp. 1056-1064
Closed Access | Times Cited: 46
A deep catalogue of protein-coding variation in 983,578 individuals
Kathie Sun, Xiaodong Bai, Siying Chen, et al.
Nature (2024) Vol. 631, Iss. 8021, pp. 583-592
Open Access | Times Cited: 23
Exploring the Multifaceted Landscape of MASLD: A Comprehensive Synthesis of Recent Studies, from Pathophysiology to Organoids and Beyond
Allison Soto, Colby Spongberg, Alessandro Martinino, et al.
Biomedicines (2024) Vol. 12, Iss. 2, pp. 397-397
Open Access | Times Cited: 22
Integrative common and rare variant analyses provide insights into the genetic architecture of liver cirrhosis
Jonas Ghouse, Garðar Sveinbjörnsson, Marijana Vujković, et al.
Nature Genetics (2024) Vol. 56, Iss. 5, pp. 827-837
Open Access | Times Cited: 18
Human-correlated genetic models identify precision therapy for liver cancer
Miryam Müller, Stephanie May, H. G. HALL, et al.
Nature (2025)
Open Access | Times Cited: 2
Metabolic dysfunction-associated steatotic liver disease in adults
Daniel Q. Huang, Vincent Wai‐Sun Wong, Mary E. Rinella, et al.
Nature Reviews Disease Primers (2025) Vol. 11, Iss. 1
Closed Access | Times Cited: 2
A phase I/II study of ARO-HSD, an RNA interference therapeutic, for the treatment of non-alcoholic steatohepatitis
Lung‐Yi Mak, Ed Gane, Christian Schwabe, et al.
Journal of Hepatology (2022) Vol. 78, Iss. 4, pp. 684-692
Closed Access | Times Cited: 40
Multiancestry exome sequencing reveals INHBE mutations associated with favorable fat distribution and protection from diabetes
Parsa Akbari, Olukayode Sosina, Jonas Bovijn, et al.
Nature Communications (2022) Vol. 13, Iss. 1
Open Access | Times Cited: 39
Advances in the genetics of nonalcoholic fatty liver disease
Veeral Ajmera, Rohit Loomba
Current Opinion in Gastroenterology (2023) Vol. 39, Iss. 3, pp. 150-155
Open Access | Times Cited: 23
Genetics of MASLD: The State of Art Update.
Silvia Sookoian, Yaron Rotman, Luca Valenti
Clinical Gastroenterology and Hepatology (2024) Vol. 22, Iss. 11, pp. 2177-2187.e3
Closed Access | Times Cited: 14
CIDE proteins and their regulatory mechanisms in lipid droplet fusion and growth
Li Xu, Li-Zhen Li, Lingzhi Wu, et al.
FEBS Letters (2024) Vol. 598, Iss. 10, pp. 1154-1169
Open Access | Times Cited: 12
Prevalence and Determinants of Liver Disease in Relatives of Italian Patients With Advanced MASLD
Serena Pelusi, Luisa Ronzoni, Jessica Rondena, et al.
Clinical Gastroenterology and Hepatology (2024) Vol. 22, Iss. 11, pp. 2231-2239.e4
Open Access | Times Cited: 8
Pharmacological treatment for metabolic dysfunction–associated steatotic liver disease and related disorders: Current and emerging therapeutic options
Xiang Zhang, Harry Cheuk-Hay Lau, Jun Yu
Pharmacological Reviews (2025) Vol. 77, Iss. 2, pp. 100018-100018
Open Access | Times Cited: 1
Recent advances in MASLD genetics: Insights into disease mechanisms and the next frontiers in clinical application
Vincent Chen, Graham F. Brady
Hepatology Communications (2025) Vol. 9, Iss. 1
Open Access | Times Cited: 1
Selection for somatic escape variants in SERPINA1 in the liver of patients with alpha-1 antitrypsin deficiency
Natalia Brzozowska, Lily Wu, Vera Khodzhaeva, et al.
Nature Genetics (2025)
Open Access | Times Cited: 1
Drug development advances in human genetics‐based targets
X. Zhang, Wenjun Yu, Yan Li, et al.
MedComm (2024) Vol. 5, Iss. 2
Open Access | Times Cited: 8
Loss of GPR75 protects against non-alcoholic fatty liver disease and body fat accumulation
Alasdair Leeson-Payne, Jean Iyinikkel, C. Malcolm, et al.
Cell Metabolism (2024) Vol. 36, Iss. 5, pp. 1076-1087.e4
Open Access | Times Cited: 7
Agonist antibody to guanylate cyclase receptor NPR1 regulates vascular tone
Michael E. Dunn, Aaron Kithcart, Jee Hae Kim, et al.
Nature (2024) Vol. 633, Iss. 8030, pp. 654-661
Open Access | Times Cited: 7
Genetics of drug‐induced liver injury: Current knowledge and future prospects
Ann K. Daly
Clinical and Translational Science (2022) Vol. 16, Iss. 1, pp. 37-42
Open Access | Times Cited: 27
Page 1 - Next Page

Scroll to top